Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study
about
sameAs
Emerging targets for antidepressant therapiesSubjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant usersNovel targets for antidepressant therapiesDiscovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporterThe monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.Monoamine reuptake inhibitors in Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.What's in the pipeline for the treatment of Parkinson's disease?Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.Non-human primate models of PD to test novel therapies.The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.Established therapies and novel targets in the treatment of Parkinson's disease.Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).
P2860
Q28247614-B2E27600-2F34-4534-BC5C-B268EFDA7739Q28284151-DE75821D-129B-45C6-85E2-16F8A74943AEQ28648254-1C312567-DF9C-4529-859C-CD4E22FFAC95Q34249476-4D99CF37-E6E1-45DF-8410-A87DE06B4492Q34429523-A3FA6EA8-C928-43BB-B1A7-68F6242616ABQ35165280-1C18DEDC-EC6C-4875-8496-EAEDCF49F330Q35589979-DB47A2A8-4B90-468D-88BA-EF01D8F13072Q37352050-B72F0D4B-E213-437A-BE93-2E0B786E164CQ37891098-1518A5EE-82FF-4A06-BDC2-D7BCC50F9255Q38837020-F747847E-F688-4BCF-B907-853EC6DDEDEDQ39229450-F80FFC35-B6E3-4637-B5FB-75CA94A5057CQ42486325-D9BCE0A1-D72C-4B8E-8D10-F2B5AD08E8CAQ42723595-33E074E3-A6DC-4DEB-BAEF-DC5B6F9BE8C9Q55421497-049EDF2F-165C-42D7-9D8C-E71613C02A6F
P2860
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@ast
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@en
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@nl
type
label
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@ast
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@en
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@nl
altLabel
Tesofensine (NS 2330), a Monoa ...... Disease and Motor Fluctuations
@en
prefLabel
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@ast
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@en
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@nl
P2093
P50
P1433
P1476
Tesofensine (NS 2330), a Monoa ...... Disease and Motor Fluctuations
@en
Tesofensine (NS 2330), a monoa ...... fluctuations: the ADVANS Study
@en
P2093
Laurence Salin
Lisa Waldhauser
Marina Aristin
Nolwenn Juhel
Thomas Schindler
P356
10.1001/ARCHNEUR.65.5.577
P407
P577
2008-05-01T00:00:00Z